drugset / Trial / NCT04902950

TXA in the Reduction of Post-Op Hematoma and Seroma in Patients Undergoing Panniculectomy or Abdominoplasty

NCT04902950 ↗

Phase 4 Terminated 9 enrolled The Reading Hospital and Medical Center
RandomizedParallel-groupTriple-blindSupportive care

Summary

The purpose of this study is to study the use of a drug, tranexamic acid (TXA) to decrease bleeding and fluid collections in patients undergoing excision of excess lower abdominal skin and soft tissue, otherwise known as a panniculectomy. The use of TXA in this study is experimental. TXA is a medication currently used in many surgical subspecialties to control bleeding. TXA is approved by the FDA as a medication taken by mouth for the treatment of heavy menstrual bleeding and as an injection in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. The use of TXA in this study is experimental, which means it is not approved by the FDA for topical use in decreasing bleeding during and after surgery. The results of this study will help the researchers determine if TXA is effective in decreasing blood loss following surgery. If effective, researchers hope this will result in earlier removal of post-operative drains leading to faster return to work or social activities

Timeline

Start
2020-08-17
Primary completion
2021-05-06
Completion
2021-05-06

Outcome

Outcome not reported

Stopped: “Logistics”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule — Topical

Indications

No indication recorded.